Brief: Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC
08/01/2025 12:57
Jan 8 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY ANNOUNCES ENCOURAGING SAFETY AND
EFFICACY DATA
IN ONGOING DOSE ESCALATION TRIALS FOR DUAL MASKED T-CELL
ENGAGERS VIR-5818 IN SOLID TUMORS AND VIR-5500 IN MCRPC
* VIR BIOTECHNOLOGY INC - VIR-5818 SHOWS 50% TUMOR SHRINKAGE
IN
HER2 CANCERS AT ≥400 ΜG/KG
* VIR BIOTECHNOLOGY INC - NO DOSE-LIMITING CRS OBSERVED FOR
VIR-5818 OR VIR-5500
* VIR BIOTECHNOLOGY INC: PROMISING SAFETY PROFILE WITH MTD
NOT YET
REACHED FOR VIR-5818 OR VIR-5500
Source text: urn:newsml:reuters.com:*:nBw4hFrQha
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO